A persistent problem remains unresolved in heart failure with preserved ejection fraction – targeted treatment for highly heterogeneous patients.

This heterogeneity can be the cause of the lack of treatment response in clinical trials, making trial success difficult.

 

 

The field needs better actionable biomarkers capable of finding the patients in most need of treatment – and that starts with PRO-C6.

 

That's where endotrophin, a product of collagen formation, comes into the picture. Endotrophin reflects the activity of key collagen-producing cells: fibroblasts. Endotrophin measured by the PRO-C6 assay, can identify HFpEF patients with a very aggressive endotype, highly affected by fibrosis.

  • PRO-C6 is a robust prognostic biomarker in HFpEF patients that can identify a population at higher risk.
  • Endotrophin can be used for trial enrichment to select a high-risk endotype in clinical studies.

Among all HFpEF endotypes, there is another, unique, patient group – the ones with high fibroblast activity, which can be quantified by PRO-C6. It doesn’t matter if you’re old, obese, or frail, your PRO-C6 can still be high.

We believe it is time to rethink how we approach patient segregation.

We need to start focusing on the fibrotic endotype.

It’s endotrophin endotyping by PRO-C6: heart failure risk stratification redefined.

Read the publication in NEJM Evidence